KalVista Pharmaceuticals (KALV) Tops Q4 EPS by 10c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q4 EPS of ($0.77), $0.10 better than the analyst estimate of ($0.87).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M
• The Fed is hiking. Why isn't UBS worried about stocks?